|
1
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chawla-Sarkar M, Bae SI, Reu FJ, et al:
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs
sensitizes resistant melanoma cells to Apo2L/TRAIL-induced
apoptosis. Cell Death Differ. 11:915–923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nomura T, Yamasaki M, Nomura Y and Mimata
H: Expression of the inhibitors of apoptosis proteins in
cisplatin-resistant prostate cancer cells. Oncol Rep. 14:993–997.
2005.PubMed/NCBI
|
|
4
|
Li F, Yang J, Ramnath N, Javle MM and Tan
D: Nuclear or cytoplasmic expression of survivin: what is the
significance? Int J Cancer. 114:509–512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hinnis AR, Luckett JC and Walker RA:
Survivin is an independent predictor of short-term survival in poor
prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olie RA, Simoes-Wust AP, Baumann B, et al:
A novel antisense oligonucleotide targeting survivin expression
induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Cancer Res. 60:2805–2809. 2000.
|
|
8
|
Pennati M, Binda M, Colella G, et al:
Ribozyme-mediated inhibition of survivin expression increases
spontaneous and drug-induced apoptosis and decreases the
tumorigenic potential of human prostate cancer cells. Oncogene.
23:386–394. 2004. View Article : Google Scholar
|
|
9
|
Liu H, Guo S, Roll R, et al: Phi29 pRNA
vector for efficient escort of hammerhead ribozyme targeting
survivin in multiple cancer cells. Cancer Biol Ther. 6:697–704.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L, Liu J, Diao Z, et al: Evaluation of
specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to
multiple tumor cells. Mol Biosyst. 5:1361–1368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy: fulfilled promises and open
questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gyurkocza B, Plescia J, Raskett CM, et al:
Antileukemic activity of shepherdin and molecular diversity of
hsp90 inhibitors. J Natl Cancer Inst. 98:1068–1077. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fortugno P, Beltrami E, Plescia J, et al:
Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA.
100:13791–13796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheung CH, Chen HH, Cheng LT, et al:
Targeting Hsp90 with small molecule inhibitors induces the
over-expression of the anti-apoptotic molecule, survivin, in human
A549, HONE-1 and HT-29 cancer cells. Mol Cancer. 9:772010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanimoto R, Sakaguchi M, Abarzua F, et al:
Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer
cells to gene-therapeutic overexpression of REIC/Dkk3. Int J
Cancer. 126:1562–1569. 2010.PubMed/NCBI
|
|
16
|
Schardt JA, Weber D, Eyholzer M, Mueller
BU and Pabst T: Activation of the unfolded protein response is
associated with favorable prognosis in acute myeloid leukemia. Clin
Cancer Res. 15:3834–3841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, He Z, Zhang J, et al:
Overexpression of endoplasmic reticulum molecular chaperone GRP94
and GRP78 in human lung cancer tissues and its significance. Cancer
Detect Prev. 29:544–551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arnaudeau S, Arboit P, Bischof P, et al:
Glucose-regulated protein 78: a new partner of p53 in trophoblast.
Proteomics. 9:5316–5327. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang WJ, Xia LM, Zhu F, et al:
Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in
response to hypoxia. Int J Cancer. 124:298–305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang M, Zhao XR, Wang P, et al: Glucose
regulated proteins 78 protects insulinoma cells (NIT-1) from death
induced by streptozotocin, cytokines or cytotoxic T lymphocytes.
Int J Biochem Cell Biol. 39:2076–2082. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang M, Wang P, Peng JL, et al: The
altered expression of glucose-regulated proteins 78 in different
phase of streptozotocin-affected pancreatic beta-cells. Cell Stress
Chaperones. 14:43–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carrasco RA, Stamm NB, Marcusson EG, et
al: Antisense inhibition of survivin expression as a cancer
therapeutic. Mol Cancer Ther. 10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sapra P, Wang M, Bandaru R, et al:
Down-modulation of survivin expression and inhibition of tumor
growth in vivo by EZN-3042, a locked nucleic acid antisense
oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 29:97–112.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakahara T, Kita A, Yamanaka K, et al:
Broad spectrum and potent antitumor activities of YM155, a novel
small-molecule surviving suppressant, in a wide variety of human
cancer cell lines and xenograft models. Cancer Sci. 102:614–621.
2011. View Article : Google Scholar
|
|
25
|
Nakahara T, Takeuchi M, Kinoyama I, et al:
YM155, a novel small-molecule survivin suppressant, induces
regression of established human hormone-refractory prostate tumor
xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar
|
|
26
|
Ashihara E, Kawata E and Maekawa T: Future
prospect of RNA interference for cancer therapies. Curr Drug
Targets. 11:345–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tirrò E, Consoli ML, Massimino M, et al:
Altered expression of c-IAP1, survivin, and Smac contributes to
chemotherapy resistance in thyroid cancer cells. Cancer Res.
66:4263–4272. 2006.PubMed/NCBI
|
|
28
|
Kappler M, Bache M, Bartel F, et al:
Knockdown of survivin expression by small interfering RNA reduces
the clonogenic survival of human sarcoma cell lines independently
of p53. Cancer Gene Ther. 11:186–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu YF, Liang XJ, Liu YY, et al: Antisense
oligonucleotide targeting survivin inhibits growth by inducing
apoptosis in human osteosarcoma cells MG-63. Neoplasma. 57:501–506.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xia C, Xu Z, Yuan X, et al: Induction of
apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
Mol Cancer Ther. 1:687–694. 2002.PubMed/NCBI
|
|
31
|
Hendruschk S, Wiedemuth R, Aigner A, et
al: RNA interference targeting survivin exerts antitumoral effects
in vitro and in established glioma xenografts in vivo. Neuro Oncol.
13:1074–1089. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kern J, Untergasser G, Zenzmaier C, et al:
GRP-78 secreted by tumor cells blocks the antiangiogenic activity
of bortezomib. Blood. 114:3960–3967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reddy RK, Mao C, Baumeister P, et al:
Endoplasmic reticulum chaperone protein GRP78 protects cells from
apoptosis induced by topoisomerase inhibitors: role of ATP binding
site in suppression of caspase-7 activation. J Biol Chem.
278:20915–20924. 2003. View Article : Google Scholar
|
|
34
|
Li J and Lee AS: Stress induction of
GRP78/BiP and its role in cancer. Curr Mol Med. 6:45–54. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saito S and Tomida A: Use of chemical
genomics in assessment of the UPR. Methods Enzymol. 491:327–341.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ni M, Zhou H, Wey S, et al: Regulation of
PERK signaling and leukemic cell survival by a novel cytosolic
isoform of the UPR regulator GRP78/BiP. PLoS One. 4:e68682009.
View Article : Google Scholar : PubMed/NCBI
|
